SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (23514)1/22/2015 7:32:31 PM
From: fred hayes  Read Replies (2) | Respond to of 23519
 
Hang in there, I just don't understand how it could be this low. Had about $343 million cash Sep 30, looks like (without digging alot) cash exceeds market cap. The ED drug looks best in class. Why isn't someone buying them out? Can't reconcile this. The RBC call looks like a no-brainer to me. As for the reference to falling knives, never paid much attention to that. Safest and largest part of any move is the first part, and tends to happen before you can do much about it. And don't forget, I have been wrong on this stock for years...(:<).

f



To: mopgcw who wrote (23514)1/23/2015 11:38:11 AM
From: The Ox  Respond to of 23519
 
I like how their target of $6/share is over 100% above the stock's price but it's only an "outperform". Seems to me if a stock could go up that much it's a screaming buy!!

I guess that's why the analyst at RBC gets paid "big money", he's staying conservative.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News